Karachaliou, Niki

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

Lin, L., Sabnis, A. J., Chan, E., Olivas, V., Cade, L., Pazarentzos, E., Asthana, S., Neel, D., Yan, J. J., Lu, X., et al. (2015) · Nature Genetics

Hippo pathway signaling and YAP/TAZMelanoma and MAPK Pathways

Cited by 551

Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients

Karachaliou, N., Gonzalez-Cao, M., Crespo, G., Drozdowskyj, A., Aldeguer, E., Gimenez-Capitan, A., Teixido, C., Molina-Vila, M. A., Viteri, S., De Los Llanos Gil, M., et al. (2018) · Therapeutic Advances in Medical Oncology

Cancer Immunotherapy and Biomarkersinterferon and immune responses

Cited by 285

Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial

Karachaliou, N., Mayo-de las Casas, C., Queralt, C., de Aguirre, I., Melloni, B., Cardenal, F., Garcia-Gomez, R., Massuti, B., Sánchez, J. M., Porta, R., et al. (2015) · JAMA Oncology

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 239

The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR -Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial

Costa, C., Molina, M. A., Drozdowskyj, A., Giménez-Capitán, A., Bertran-Alamillo, J., Karachaliou, N., Gervais, R., Massuti, B., Wei, J., Moran, T., et al. (2014) · Clinical Cancer Research

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 229

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): An international, multicentre, single-arm, phase 2 trial

Rosell, R., Dafni, U., Felip, E., Curioni-Fontecedro, A., Gautschi, O., Peters, S., Massutí, B., Palmero, R., Aix, S. P., Carcereny, E., et al. (2017) · The Lancet Respiratory Medicine

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 182

BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale

Bracht, J. W. P., Karachaliou, N., Bivona, T., Lanman, R. B., Faull, I., Nagy, R. J., Drozdowskyj, A., Berenguer, J., Fernandez-Bruno, M., Molina-Vila, M. A., et al. (2019) · Cancers

Lung Cancer Treatments and MutationsMelanoma and MAPK Pathways

Cited by 67

Cancer stem cell biomarkers in egfr-mutation–positive non–small-cell lung cancer

Codony-Servat, J., Codony-Servat, C., Cardona, A. F., Giménez-Capitán, A., Drozdowskyj, A., Berenguer, J., Bracht, J. W. P., Ito, M., Karachaliou, N., & Rosell, R. (2019) · Clinical Lung Cancer

Lung Cancer Treatments and MutationsCancer Cells and Metastasis

Cited by 46